Muscle Atrophy - Pipeline Review, H2 2019

November 2019 | 37 pages | ID: MBF48C48A2BEN
Global Markets Direct

Abstracts

Muscle Atrophy - Pipeline Review, H2 2019

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Muscle Atrophy - Pipeline Review, H2 2019, provides an overview of the Muscle Atrophy (Musculoskeletal Disorders) pipeline landscape.

Muscle atrophy is the wasting or loss of muscle tissue. Symptoms of muscle atrophy include muscle damage, pain, weak muscles, loss of movement, facial weakness and numbness or tingling in arms or legs. Causes include aging, nerve diseases, stroke, motor neuropathy, muscular dystrophy and arthritis. Treatment includes exercise, dietary changes and surgery.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Muscle Atrophy - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Muscle Atrophy (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Muscle Atrophy (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Muscle Atrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Preclinical, Discovery and Unknown stages are 7, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Muscle Atrophy (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Muscle Atrophy (Musculoskeletal Disorders).
• The pipeline guide reviews pipeline therapeutics for Muscle Atrophy (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Muscle Atrophy (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Muscle Atrophy (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Muscle Atrophy (Musculoskeletal Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Muscle Atrophy (Musculoskeletal Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Muscle Atrophy (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Muscle Atrophy - Overview
Muscle Atrophy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Muscle Atrophy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Muscle Atrophy - Companies Involved in Therapeutics Development
Avidity Biosciences LLC
Emmyon Inc
Hana Pharm Co Ltd
Helixmith Co Ltd
K-Stemcell Co Ltd
Milo Biotechnology LLC
Shionogi & Co Ltd
Teijin Pharma Ltd
Muscle Atrophy - Drug Profiles
AAV9-Follistatin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotides for Muscle Atrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EMMY-105 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EMMY-106 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Muscular Atrophy, Sarcopenia and Traumatic Nerve Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HNP-6005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JP-4039 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit HSD11B1 for Muscle Atrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Parry-Romberg disease and Thromboangiitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TEISARM-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Muscle Atrophy - Dormant Projects
Muscle Atrophy - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Muscle Atrophy, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Muscle Atrophy - Pipeline by Avidity Biosciences LLC, H2 2019
Muscle Atrophy - Pipeline by Emmyon Inc, H2 2019
Muscle Atrophy - Pipeline by Hana Pharm Co Ltd, H2 2019
Muscle Atrophy - Pipeline by Helixmith Co Ltd, H2 2019
Muscle Atrophy - Pipeline by K-Stemcell Co Ltd, H2 2019
Muscle Atrophy - Pipeline by Milo Biotechnology LLC, H2 2019
Muscle Atrophy - Pipeline by Shionogi & Co Ltd, H2 2019
Muscle Atrophy - Pipeline by Teijin Pharma Ltd, H2 2019
Muscle Atrophy - Dormant Projects, H2 2019
Muscle Atrophy - Discontinued Products, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development for Muscle Atrophy, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

Avidity Biosciences LLC
Emmyon Inc
Hana Pharm Co Ltd
Helixmith Co Ltd
K-Stemcell Co Ltd
Milo Biotechnology LLC
Shionogi & Co Ltd
Teijin Pharma Ltd